Navamedic ASA: Q1 2021 financial
Oslo, 11 May 2021 – Navamedic ASA (OSE: NAVA) grew revenues by 5.4% in the first quarter of 2021 compared to the same quarter last year. The company reported revenues of NOK 58.6 million in the first quarter of 2021 with an EBITDA of NOK 2.6 million, driven by both new products, underlying growth and an improved revenue mix. The company reiterates its mid- to long-term ambition of building a NOK 500 million company.“In the first quarter of 2021, we continued to deliver growth in our underlying portfolio. The rapid growth of specialty pharma product Mysimba and the consumer health products